Displaying drugs 326 - 350 of 407 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Ixekizumab | 146158.0 C6492H10012N1728O2028S46 |  | A monoclonal antibody used to treat moderate to severe plaque psoriasis. | Interleukin Inhibitors |
| Odesivimab | 146164.54 C6506H10024N1720O2030S42 | | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. | Antiviral Agents |
| Muromonab | 146189.7 C6460H9946N1720O2043S56 |  | A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients. | Selective Immunosuppressants |
| Durvalumab | 146300.0 C6502H10018N1742O2024S42 | | An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Mosunetuzumab | 146300.0 C6515H10031N1725O2025S43 | | A humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma. | Amino Acids, Peptides, and Proteins / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antineoplastic Agents / Blood Proteins / Cancer immunotherapy / CD20-directed Antibody Interactions / CD3-directed Antibody Interactions / Immunoglobulins / Immunosuppressive Agents / Immunotherapy / Myelosuppressive Agents / Proteins / Serum Globulins |
| Nirsevimab | 146300.0 C6494H10060N1708O2050S46 | | A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. | Antiviral monoclonal antibodies |
| Vedolizumab | 146837.0 C6528H10072N1732O2042S42 |  | An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. | Selective Immunosuppressants |
| Dupilumab | 146896.9522 C6512H10066N1730O2052S46 | | A monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults. | Agents for Dermatitis, Excluding Corticosteroids |
| Golimumab | 146943.1937 C6530H10068N1752O2026S44 |  | A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Reslizumab | 147000.0 |  | An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults. | Anti-Asthmatic Agents / Interleukin-5 Antagonist |
| Belimumab | 147000.0 C6358H9904N1728O2010S44 |  | A B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy. | Selective Immunosuppressants |
| Ublituximab | 147000.0 | | A low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis. | Selective Immunosuppressants |
| Avelumab | 147000.0 C6374H9898N1694O2010S44 | | An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Tralokinumab | 147000.0 C6374H9822N1698O2014S44 | | A monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy. | Agents for Dermatitis, Excluding Corticosteroids |
| Galcanezumab | 147000.0 | | A calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches. | Calcitonin Gene-Related Peptide (CGRP) Antagonists / Calcitonin Gene-Related Peptide Receptor Antagonists |
| Talquetamab | 147000.0 C6410H9938N1716O2006S45 | | A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. | Amino Acids, Peptides, and Proteins / Antibodies, Monoclonal / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Bispecific Monoclonal Antibodies / Blood Proteins / Immunoglobulins / MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES / Proteins / Serum Globulins |
| Sutimlimab | 147000.0 C6436H9934O2012N1700S46 | | A monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease. | Complement Inactivating Agents / Selective Immunosuppressants |
| Tezepelumab | 147000.0 C6400H9844N1732O1992S52 | | A human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Blood Proteins / Drugs for Obstructive Airway Diseases / Globulins / Immunoglobulins / Immunoproteins / Proteins / Serum Globulins / Thymic Stromal Lymphopoietin Blocker |
| Mirikizumab | 147000.0 | | An anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis. | Anti-Ulcer Agents / Gastrointestinal Agents |
| Eculizumab | 148000.0 |  | A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). | Selective Immunosuppressants |
| Obiltoxaximab | 148000.0 | | A monoclonal antibody used for prophylaxis or treatment of inhalational anthrax. | Antibacterial monoclonal antibodies / Specific Immunoglobulins |
| Ipilimumab | 148000.0 C6572H10126N1734O2080S40 |  | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. | Antibodies, Monoclonal |
| Tocilizumab | 148000.0 C6428H9976N1720O2018S42 |  | An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). | Interleukin Inhibitors |
| Pertuzumab | 148000.0 |  | An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. | Antibodies, Monoclonal / HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors |
| Anifrolumab | 148000.0 | | A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus. | Selective Immunosuppressants |
Displaying drugs 326 - 350 of 407 in total